Company: IMNN
Filing Date: 2025-04-04
Form Type: S-1
Source: 0001641172-25-002783
Chunk: 20

Company: Imunon, Inc.
Filing Date: 2025-04-04
Form: S-1
Chunk 20
---
Purchasers who purchase our securities in this offering pursuant to a securities purchase agreement may have rights not available to purchasers that purchase without the benefit of a securities purchase agreement.

In addition to rights and remedies available to all purchasers in this offering under federal securities and state law, the purchasers that enter into a securities purchase agreement will also be able to bring claims of breach of contract against us. The ability to pursue a claim for breach of contract provides those investors with the means to enforce the covenants uniquely available to them under the securities purchase agreement.

We have never paid dividends on our capital stock, and we do not anticipate paying dividends in the foreseeable future.

We have never paid dividends on any of our capital stock and currently intend to retain any future earnings to fund the growth of our business. We may also enter into credit agreements or other borrowing arrangements in the future that will restrict our ability to declare or pay cash dividends on our Common Stock. Any determination to pay dividends in the future will be at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant. As a result, capital appreciation, if any, of the securities will be the sole source of gain, if any, for the foreseeable future.

| 9 |

<div align='center'>CAPITALIZATION</div>

The following table sets forth our consolidated cash and cash equivalents and capitalization as of December 31, 2024:

| ● | on                                                                                                                               
 an actual basis; and                                                                                                             |
| ● | on                                                                                                                               
 an as adjusted basis to give effect to the sale of 10,000,000 shares of Common Stock and accompanying common warrants in the     
 offering at an assumed public offering price of $1.00 per share of Common Stock and accompanying warrant (which was the closing  
 price of our Common Stock on Nasdaq on April 3, 2025), after deducting Placement Agents fees and estimated offering expenses     
 payable by us, and assuming no sale of any pre-funded warrants in this offering and no exercise of the common warrants issued in 
 connection with this offering.                                                                                                   |

You should read the following table in conjunction with the sections entitled “ Use of Proceeds” included elsewhere in this prospectus and “ Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2024,